TABLE 4.
Percent loss in neutralization of polyclonal DENV4 immune and vaccine sera against rDENV4/3a
| Serum type | Serum sample | Reciprocal of Neut50 titers against DENV4 and rDENV4/3 |
% loss in neutralization | |
|---|---|---|---|---|
| DENV4 | rDENV4/3 | |||
| DENV4 immune sera | 002 | 115 | 44 | 62 |
| 102 | 153 | 31 | 80 | |
| 112 | 1,746 | 1,609 | 8 | |
| 07/333 | 1,256 | 399 | 69 | |
| 06/302 | 1,660 | 1,058 | 37 | |
| 06/105 | 399 | 204 | 49 | |
| DENV4 vaccine immune sera | 256.03.36 | 562 | 178 | 69 |
| 256.03.38 | 255 | 5 | 98 | |
| 256.03.57 | 153 | 5 | 97 | |
| 256.03.68 | 1,167 | 276 | 76 | |
a
A U937+DC-SIGN flow cytometry-based neutralization assay was performed with primary DENV4 infection sera or DENV4 monovalent vaccine immune sera and WT DENV4 or rDENV4/3 viruses. Neut50 titers were calculated. Samples that did not block 50% of infection at the highest concentration were assigned a value of 5. The mean percentages of loss in neutralization with rDENV4/3 in both naturally infected immune sera and vaccine sera were significant (P = 0.005 and P = 0.002, respectively) by a one-sample t test performed to evaluate the relative (percent) difference scores created from the paired loss-of-neutralization data.